Update

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹1087.00

prior close

₹1096.45

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-1.5%+1.0% vs market

Pharmaceuticals peers, median of 162sector-0.5%+0.0% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty 100 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.5

10m

+1.2

15m

+1.2

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-1.5+1.0-0.5+0.0

Next day

+0.2-2.3+2.5-1.2+1.4

-0.6-1.9+1.3-1.5+0.8

-1.0-2.3+1.2-1.6+0.6

-0.3-2.2+1.9-1.1+0.8

+0.3-2.3+2.6-1.3+1.7

+1.5-2.8+4.3-1.0+2.5

15d

-1.4+0.5-1.8+1.3-2.6

+3.4+0.0+3.4+2.3+1.1

+3.2+1.3+1.9+5.3-2.0

+6.8+1.1+5.8+6.9-0.0

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences, announced that the US FDA granted Priority Review to the New Drug Application for saroglitazar. The drug is proposed for treating Primary Biliary Cholangitis (PBC) either in combination with ursodeoxycholic acid (UDCA) for patients with inadequate response, or as monotherapy for those unable to tolerate UDCA. The FDA has assigned a PDUFA target action date of November 27, 2026. Priority Review is typically granted for drugs that could offer significant improvements in safety or effectiveness.

Likely market impact

Priority Review status signals FDA's recognition of potential therapeutic value, which could accelerate the drug's path to market. A successful approval would expand Zydus's US product portfolio and create a new revenue stream in the PBC treatment space.